Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Gut microbiome is associated with recurrence-free survival in patients with resected high-risk melanoma receiving adjuvant immune checkpoint blockade.

Cell·2026

Same author

Artificial Intelligence Algorithm Predicts Response to Immune Checkpoint Inhibitors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025

Same author

Efficacy of CTLA-4 checkpoint therapy is dependent on IL-21 signaling to mediate cytotoxic reprogramming of PD-1<sup>+</sup>CD8<sup>+</sup> T cells.

Nature immunology·2024

Same author

Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Melanoma: Analyses From CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 Trials.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024

Same author

Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8<sup>+</sup> T cells.

Cancer cell·2024

Same author

T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study.

Cancer discovery·2024

Search research articles

Related Experiment Video

Updated: Mar 1, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Biomarkers for Checkpoint Inhibition.

Jeffrey S Weber¹

¹From the Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting

|June 1, 2017

Summary

Identifying predictive biomarkers for cancer immunotherapy response remains crucial. Current approaches focus on tumor microenvironment factors, but challenges like accessibility and heterogeneity necessitate novel, combined biomarker strategies for predicting treatment success.

More Related Videos

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

Related Experiment Videos

Last Updated: Mar 1, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

Area of Science:

Oncology
Immunology
Biomarker Discovery

Background:

Cancer immunotherapy, particularly checkpoint blockade, shows promise but requires predictive biomarkers for patient selection.
Key factors for immunotherapy success include immune cell infiltration, tumor microenvironment inflammation, and neoantigen availability.

Purpose of the Study:

To review the current understanding of biomarkers predicting response to cancer immunotherapy.
To identify challenges in current biomarker assessment and discuss future directions for predictive biomarker development.

Main Methods:

Literature review of recent advancements in cancer immunotherapy biomarkers.
Analysis of genetic factors contributing to resistance against programmed cell death protein 1 (PD-1) blockade.
Discussion of practical challenges in biomarker implementation, such as tumor biopsy acquisition and heterogeneity.

Main Results:

Immune cell infiltrate, inflammatory signatures, and neoantigens are critical for checkpoint blockade efficacy.
Mutations in T-cell signaling pathways can cause innate or adaptive resistance to PD-1 blockade.
Tumor heterogeneity, accessibility, and biomarker inducibility pose significant hurdles.

Conclusions:

Predicting immunotherapy response is complex, with current biomarkers facing limitations.
Peripheral blood or serum biomarkers alone are unlikely to reliably predict outcomes.
An integrated biomarker approach combining tumor and host factors is essential for predicting patient response to checkpoint inhibition.